FDA Approves Velsipity for Moderate-to-Severe Ulcerative Colitis in Adults
TUESDAY, Oct. 17, 2023 (HealthDay News) -- The U.S. Food and Drug Administration approved Velsipity (etrasimod) for adults with moderately to severely active ulcerative colitis (UC).
The approval was based on results from the ELEVATE UC phase 3 registrational program (ELEVATE UC 52 and ELEVATE UC 12) that included UC patients who had previously failed or were intolerant to at least one conventional, biologic, or Janus kinase inhibitor therapy. In ELEVATE UC 52, 27.0 percent of patients receiving Velsipity achieved clinical remission versus 7.0 percent of patients receiving placebo at week 12, and at week 52, clinical remission was achieved by 32.0 and 7.0 percent, respectively. In ELEVATE UC 12, 26.0 percent of patients receiving Velsipity achieved clinical remission versus 15.0 percent of patients receiving placebo. At week 12, all key secondary efficacy end points were met, including endoscopic improvement and mucosal healing.
The selective sphingosine-1-phosphate receptor modulator was approved at a 2-mg recommended dose. The safety of Velsipity was consistent with previous studies, with the most common adverse reactions being headache, elevated liver tests, and dizziness (incidence ≥5 percent).
"Velsipity provides adults living with moderately-to-severely active UC the opportunity to achieve steroid-free remission with an oral, once-daily pill that has a favorable benefit-risk profile," Angela Hwang, Pfizer chief commercial officer and president of global biopharmaceuticals business, said in a statement.
Approval of Velsipity was granted to Pfizer.
Related Posts
Aspirin Use Not Tied to Clinical Outcomes in Nonobstructive CAD
MONDAY, May 2, 2022 (HealthDay News) -- For individuals with nonobstructive...
AHA News: Get Past Its Spines and Reap Health Benefits From the Prickly Pear Cactus
FRIDAY, Aug. 4, 2023 (American Heart Association News) -- Covered in menacing...
Home Drug Infusions Can Be Dangerous, But Many Home Care Staff Aren’t Trained
MONDAY, Jan. 23, 2023 (HealthDay News) -- Intravenous (IV) lines are generally...
Women Less Likely to Ask for More Time When Deadlines Loom
WEDNESDAY, Nov. 3, 2021 (HealthDay News) -- It's a case of being your own worst...